WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

High manufacturing costs are limiting patient access to CAR T cell therapies, according to new research, which indicates that decentralization, vector-free modification technologies, and AI would help ...

So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

CD19 chimeric antigen receptor (CAR) T-cell therapy showed potential in treating patients with refractory systemic lupus erythematosus (SLE), with B-cell depletion and disease activity reduction ...

Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence ...